NCT02220725View on ClinicalTrials.gov

A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban

PHASE3CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Bleeding
Interventions
BIOLOGICAL

Andexanet

OTHER

Placebo

Trial Locations (1)

90630

West Coast Clinical Trials, Cypress

Sponsors
All Listed Sponsors
lead

Portola Pharmaceuticals

INDUSTRY

NCT02220725 - A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban | Biotech Hunter | Biotech Hunter